Genetown

Found 53,339 articles

• Analgesic Solutions Announces New Executive Management Team

  9/21/2018

  Analgesic Solutions LLC, a company that focuses on increasing assay sensitivity in the conduct of clinical trials through consulting, innovative tools, data science, technology and training, announced today changes within its leadership structure.

• Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

  9/21/2018

  Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

• Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device

  9/21/2018

  New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience

• SCIEX Presenting New Applications at Global CESI-MS Symposium 2018

  9/21/2018

  Innovations in ultra low-flow separation and accurate mass analysis expands into proteomics, metabolomics, food and environmental monitoring

• Agenus Closes $15 Million Partial Royalty Monetization With XOMA

  9/21/2018

  Agenus Inc. cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation

• 

  Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million

  9/20/2018

  Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.

• GI Dynamics Announces AUD $6.9m Private Placement to be Completed in Two Tranches

  9/20/2018

  GI Dynamics, Inc. is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company

• Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

  9/20/2018

  Cardurion Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733

• Wolters Kluwer Launches Newest Version of Surveillance Solution Amid Growing Threat of Superbugs

  9/20/2018

  Wolters Kluwer, Health, released today the newest version of its industry-leading clinical surveillance solution, Sentri7®.

• Harbor Homes becomes first healthcare organization in New Hampshire to utilize OARS technology to improve treatment for opioid use disorder

  9/20/2018

  Q2i announces that New Hampshire-based Harbor Homes and member of the Partnership for Successful Living, is test piloting the Opioid Addiction Recovery Support (OARS) mobile app to support patients in Medication-Assisted Treatment (MAT) programs

• BlueRock Therapeutics Appoints Shane Kovacs as Chief Business and Financial Officer

  9/20/2018

  Appointment strengthens the leadership team and accelerates the company's establishment of its novel Cell+Gene platform

• Gentle Dental Partners is Now 42 North Dental

  9/20/2018

  The new name was created to better reflect all the 42 North Dental supported practices comprised of 57 dental practices representing 14 patient-facing brands across 4 New England states.

• Thermo Fisher Scientific to Launch Global Customer Solution Centers

  9/20/2018

  Supporting scientists through the collaborative development of next generation chromatography and mass spectrometry solutions in Pharma/Biopharma and Food/Beverage Industries

• Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018

  9/20/2018

  Biomarker Data Show that Molecular Target of Vicinium™, EpCAM, Expressed in Nearly All High-Grade NMIBC Patients

• Merrimack Receives $5 Million Milestone Payment from Shire

  9/20/2018

  Merrimack Pharmaceuticals, Inc. today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017.

• Axol Bioscience Opens US Office

  9/20/2018

  Axol, the rapidly growing specialist in human cell culture, is delighted to announce it has opened a new operational hub in the US.

• Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

  9/20/2018

  Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer.

• Devoted Health Receives License from State of Florida

  9/20/2018

  New Healthcare Company to Offer Medicare Advantage Plans in 2019

• Companies join forces to showcase how AI algorithms can progressively be adopted in study conduct, at DPharm 2018

  9/20/2018

  Pioneering partners Cmed and Innovative Physics have combined forces to showcase The Real Time Medical Imaging Users Tool Kit®, which uses artificial intelligence to support secure, rapid diagnostics in clinical trials, at DPharm 2018.

• Blue Cross Blue Shield of Massachusetts Among Nation's Highest-Rated Health Plans for Quality

  9/20/2018

  Blue Cross is in top 10 percent of plans nationally